New clinical trial of treatment for Severe Asthma 5th December 2016

Prof Ian Sabroe and the RHH Clinical Research Facility have initiated a clinical trial investigating Fevipiprant, a new treatment which can be taken orally as a tablet, developed by Novartis for people with severe asthma. Previous research has shown that eosinophils (a type of white blood cell) are implicated in the development of asthma. Fevipiprant has been shown to reduce the level of eosinophils. This trial will look at the efficacy of the new drug when it is added to existing therapies, and the effect on lung function, asthma exacerbations and quality of life.